
Experimental vaccine for common cancer shows potential in clinical trial
Fox News
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.
Results from the phase 1 clinical trial, published in the journal Nature, revealed that the vaccine triggered an immune response in a small patient group. "The ability to trigger a robust, long-lasting immune response is a requisite feature for any cancer vaccine." "If you can do this in pancreatic cancer, theoretically you may be able to develop therapeutic vaccines for other cancer types." Angelica Stabile is a lifestyle reporter for Fox News Digital.
This immune-cell activation persisted for nearly four years after treatment, the release stated.













